In this part of the review, we will be thoroughly discussing the main studies tackling biologics as treatment in FMF children, namely, anti-IL-1 (anakinra, canakinumab, and rilonacept), anti-TNF-α (etanercept, adalimumab, and infliximab), and anti-IL-6 notably tocilizumab (Figure 1). Here, IL1A is linked to familial Mediterranean fever.